Kornimate/medical-research-clean huggingface dataset:
impact of acarbose on abnormal glucose regulation in patients with coronary artery disease (aaa trial)

Conditions: Diabetes Mellitus; Impaired Glucose Tolerance; Coronary Artery Disease

Summary: the objective of this trial is to investigate the effect of early treatment of glucose toxicity with acarbose, a drug to control postprandial hyperglycemia, on the occurence of cardiovascular events and the inhibition of atherosclerosis.

acarbose suppresses the postprandial increase in plasma glucose levels by inhibiting the activities of alpha-amylase and alpha-glucosidase involved in digestion and absorption of carbohydrates in the intestine. a clinical study involving patients with type 2 diabetes demonstrated that acarbose decreased the post-load glucose level and improved glycosylated hemoglobin control. a prospective study involving patients with impaired glucose tolerance (igt) demonstrated that acarbose inhibited progression to type 2 diabetes and significantly reduced the risk of cardiovascular diseases. it has also been reported that acarbose slows increase in the intima-media thickness and inhibits the progression of atherosclerosis. a significant proportion of patients with acute coronary syndrome and those with stable angina pectoris suffer from diabetes or igt, and their prognosis is poor.

Eligibility criteria:
inclusion criteria: * patients who have been diagnosed with coronary artery disease, with type 2 diabetes or impaired glucose tolerance exclusion criteria: * patients scheduled to undergo revascularization at the time of enrollment * patients who are being treated with an oral hypoglycemic drug or an insulin preparation * patients with a history of laparotomy of ileus * pre- and postoperative patients or individuals with severe infection or serious trauma * patients with gastrointestinal disorders such as diarrhea and vomiting * patients with a history of hypersensitivity to acarbose * pregnant or possibly pregnant women * patients who are judged by the attending physician to be otherwise ineligible

Keywords: acarbose diabetes mellitus impaired glucose tolerance coronary artery disease
the effects of dbs of subthalamıc nucleus on functionality in patıents with parkinson's disease: short-term results

Conditions: Parkinson Disease; Surgery; Respiration; Decreased; Muscle Weakness

Summary: parkinson's disease is a progressive chronic neurodegenerative disease. in cases where drug treatment is insufficient and drug use is not possible due to drug side effects, highly effective and low-risk surgical treatment options could be used. in parkinson's disease; findings such as chest wall rigidity and weakness of the respiratory muscle strength occur. the aim of this study was to determine the effect of preop and postop dbs surgery on respiratory muscle strength, respiratory function and physical performance in patients with parkinson's disease.

in the study, at least 10 patients with parkinson's disease who had dbs surgery in mustafa kemal university research and practice hospital, department of brain and nerve surgery will be evaluated. demographic-physical features, pulmonary functions, respiratory muscle strength, exercise capacity, functionality, and muscle strength will be evaluated

Eligibility criteria:
inclusion criteria: * lack of any neurological disease other than parkinson's * dbs surgery to be performed in the stn region exclusion criteria: * patients with advanced cognitive impairment * patients with pulmonary, neurological and orthopedic diseases affecting functionalities * pregnancy * patients in whom the stimulation was canceled due to infection after surgery.
do patient educational videos improve pain and recovery after laparoscopic hysterectomy?

Conditions: Pain, Postoperative

Summary: the use of multi-model patient education has been used in a variety of medical specialties to educate patients on expectations for various medical procedures and improve patients' understanding of their own health care. however, it is unknown what type of audio and/or visual materials work best in a given clinical setting. by surveying overall pain/post-operative recovery satisfaction we can measure how well our video intervention educates and reinforces post-operative management at home when compared to the current method of education that patients receive at the pre-operative visit prior to laparoscopic hysterectomy at this institution.


Eligibility criteria:
inclusion criteria: * 18y/o or older * planned for a laparoscopic hysterectomy for benign indications exclusion criteria: * inability to consent * language other than english * conversion to laparotomy, vnotes (a type of laparoscopic assisted vaginal hysteroectomy) * vaginal hysterectomy * chronic opioid use prior to surgery
foresight intracardiac echocardiography (ice) system

Conditions: Atrial Fibrillation

Summary: this study will evaluate the efficacy of 2d forward-looking and 3d intracardiac echocardiography (ice) to guide septal punctures during atrial fibrillation ablation procedures.

this study is part of a multiphase study. phase 1 involves 10 patients at a single centre. phase 2 will be done a multi centre study.

Eligibility criteria:
inclusion criteria: * patient is at least 18 years old. * patient is undergoing an atrial fibrillation ablation procedure. * patient has a transesophageal echocardiogram (tee) within the 48 hours prior to ablation procedure to rule out left atrial thrombus. * patient provides informed, written consent for participation in the study. exclusion criteria: * patients in whom placement of an ice catheter in the right atrium for adequate atrial visualization is not technically feasible (as evaluated and determined by the physician performing the procedure). * patients in whom transseptal puncture is relatively contraindicated. * patients in whom left atrial clot or dense spontaneous contrast is identified on tee, which would increase thromboembolic risk. * women of child bearing potential, in whom pregnancy cannot be excluded. * patients unable to grant informed, written consent for participation in the study.
role of epicardial adipose tissue in coronary artery disease

Conditions: Coronary Artery Disease; Obesity

Summary: we sight to evaluate whether patients with coronary artery disease (cad) have more epicardial fat than patients without cad, which would suggest that epicardial fat may be more than an "innocent bystander" and be actively involved in the disease process. its role as a modulator of vascular response and myocardial function could potentially lead to new areas of cardiac research. we also sight to evaluate whether epicardial fat from patients with cad releases more adipokines than subcutaneous fat from these patients which could prompt studies into the differential regulation of adipokine secretion in this tissue. thus for e.g., the use of thiazolidinediones (glitazones), statins, arbs or other compounds that can specifically modulate adipokine secretion could be explored to determine their benefit in ameliorating the effects attributable to increased epicardial fat.


Eligibility criteria:
inclusion criteria: * all patients elegible for elective cardiac surgery are elegible * ability to provide written informed consent in accordance with gcp guidelines and local legislations. * \> 18 years of age exclusion criteria: * control patients will not have clinical signs of cad and will show normal coronary arteries on angiography. * any medical, social or geographic condition, which, in the opinion of the investigator would not allow safe or reliable completion of the protocol.

Keywords: coronary artery disease epicardial adipose tissue epicardial fat obesity
the sleeptracktxt2 randomized trial with air-medical personnel

Conditions: Poor Quality Sleep; Fatigue

Summary: the overarching goal of this proposal is to address the medevac foundation priority of educational techniques and technologies and improve helicopter emergency medical services (hems) safety by determining if overall sleep quality and intra-shift fatigue of hems clinicians can be improved with real-time assessment and intervention. aim 1: to determine the short-term impact of an enhanced sleeptracktxt intervention on hems clinician fatigue reported in real-time during and at the end of shift work. aim 2: to determine the long-term impact of the sleeptracktxt intervention on sleep quality and sleep health indicators including hours of sleep and recovery between shift work.

the investigators will examine short term impact by examining self-reported fatigue captured at the start, during, and end of scheduled shifts. the investigators will determine longer-term impact on sleep quality by comparing scores on the pittsburgh sleep quality index (psqi) taken at baseline and then again at 4 months.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * working clinically at a study site * currently working in shifts * has a smart phone and * willing to take part in a research study that requires the sending and receiving of multiple text messages daily over 4-months exclusion criteria: * does not meet inclusion criteria
evaluation safety and explore efficacy long-term follow-up study on subjects receiving smup-ia-01 or active control

Conditions: Knee Osteoarthritis

Summary: this is a follow-up study to investigate the long-term safety and explore efficacy of smup-ia-01, for the treatment of knee osteoarthritis. subjects who participated in and completed the initial stage of the phase ii trial (nct05182034) will be followed-up until 60 months.

the subjects will be followed up at 12-month, 24-month, 36-month, 48-month and 60-month after the initial administration of smup-ia-01.

Eligibility criteria:
inclusion criteria: 1. subject who completed the safety and explore efficacy evaluations in smup-ia-01 phase ii clinical trial. 2. subject who voluntarily decided to participate and signed the consent form after receiving explanations on the clinical trial. exclusion criteria: 1. subject who were not enrolled in phase ii clinical trial of smup-ia-01 for assessing safety and explore efficacy. 2. other subjects, excluding those listed above, who were deemed unsuitable by the pi

Keywords: human umbilical cord blood derived mesenchymal stem cells huc-mscs knee osteoarthritis
bk virus and renal dysfunction in postoperative/posttraumatic critically ill patients

Conditions: Acute Renal Failure; SIRS; Sepsis; Critically Ill; Multiple Organ Dysfunction Syndrome

Summary: the purpose of this study is to find out whether acute renal failure is associated with bk virus reactivation in postoperative/posttraumatic critically ill patients with severe sirs/sepsis and shock.

polyomavirus bk virus (bkv) infection and nephropathy is a significant cause of allograft dysfunction in kidney transplantation. clinical manifestation ranges from bk viremia and nephritis to renal dysfunction. it has been suggested that bk virus reactivation alone is not sufficient to cause bk viremia and nephropathy, thus a second hit is essential for kidney specific damage, such as an inflammatory reaction or ischemia. critically ill postoperative/posttraumatic patients via the systemic inflammatory response syndrome (sirs) and the compensatory antiinflammatory response syndrome (cars) are at increased risk to develop organ dysfunctions, such as acute renal failure. cars, reflecting postoperative/posttraumatic immunosuppression, may favor viral reactivation. however, prevalence of bk viremia in critically ill postoperative/posttraumatic patients has up to now not been systematically evaluated. moreover, it is not known whether bk viremia is associated with a distinct biomarker pattern in these patients. therefore, the present study is performed to clarify whether postoperative/posttraumatic immunosuppression is associated with bk viremia, and acute renal failure with bk virus reactivation, respectively.

Eligibility criteria:
inclusion criteria: * critically ill, postoperative/posttraumatic patients with threatening acute renal failure exclusion criteria: * life expectancy \< 24 hours * participation in other trials * known or suspected pregnancy

Keywords: bk virus acute renal failure hemodiafiltration humans patients polytrauma surgery complement inflammation inflammatory response biomarkers cytokines cell surface markers functional polymorphisms infections systemic inflammatory response syndrome sirs sepsis severe sepsis shock organ dysfunctions sofa severity of disease apacheii sapsii spaps3 length of stay outcome mortality
a 12-week study to evaluate the efficacy and safety of hp-5000 in subjects with osteoarthritis pain of the knee

Conditions: Osteoarthritis Pain of the Knee

Summary: a 12-week, randomized, double-blind, placebo-controlled, parallel-group phase 3 study to evaluate the efficacy and safety of hp-5000 in subjects with osteoarthritis (oa) pain of the knee

this is a multi-center, randomized, double-blind, and placebo-controlled phase 3 study evaluating the safety and efficacy of hp-5000 in subjects with oa pain of the knees. the study will consist of up to a 28-day screening phase that will include a washout period of current prescription and over the counter (otc) analgesics; a 12-week double-blind treatment phase, and a 1-week safety follow-up phase.

Eligibility criteria:
inclusion criteria: * male or female aged 40 to 85 years with a clinical diagnosis of oa of the target knee according to the american college of rheumatology criteria. * has an x-ray of the target knee, taken no more than 1 year before baseline, showing evidence of oa. * has pain of oa in the designated/target study knee. exclusion criteria: * body mass index (bmi) \> 40. * any subject who did not follow the restriction of prohibited therapies during washout period. * arthritis of the target knee that is not caused by oa but caused by diseases such as rheumatoid arthritis, gout, psoriasis, syphilitic arthropathy, ochronosis, metabolic or other primary bone disease, or acute traumatic injury.
zero-time exercise for depression

Conditions: Depression

Summary: this study will examine the feasibility and effectiveness of a new lifestyle-integrated exercise, viz. zero-time exercise (ztex), for the management of depressive symptoms in chinese adults in hong kong. ztex refers to the integration of simple strength- and stamina-enhancing physical activity into daily life, which can be done anytime, anywhere and by anyone. depression is often accompanied by a tendency to sedentary behaviours and sleep disturbances, and sedentary lifestyles is associated with depression. the conventional psychological treatment approach for depression, viz. cognitive behavioural therapy (cbt), emphasises the relationship between activity and mood. one of the treatment components in cbt for depression, viz. behavioural activation (ba), aims to promote activity engagement that are reinforcing and consistent with the long-term goals in reducing sedentary behaviour and increasing physical activity. the simple and brief ztex uses a foot-in-the-door approach to initiate simple behaviour change as an entry-level step for facilitating ba for participants with depression. a pilot randomized controlled trial (rct) has shown some evidence on the effectiveness of ztex on improving insomnia. however, investigators have found no rct on the effectiveness of ztex for the management of depressive symptoms.


Eligibility criteria:
inclusion criteria: * hong kong residents aged 18-65 years * cantonese language fluency * patient health questionnaire (phq-9) score ≥ 10 and ≤ 14; and * willingness to provide informed consent and comply with the trial protocol. exclusion criteria: * pregnancy; * have high levels of suicidal ideation (referral information to professional services will be provided); * unstable psychotropic drugs within 2 weeks before study entry and throughout the treatment phase; * current involvement in psychotherapy for depression; * having unsafe conditions and are not recommended for exercising by physicians; and * major psychiatric, medical or neurocognitive disorders that would make participation infeasible or interfere with the adherence to physical exercising.

Keywords: zero-time exercise depression lifestyle behavioural activation
switching to potential reduced exposure products in adult smokers

Conditions: Tobacco Use Disorder; Oral Nicotine Pouch Use; Smoking Behaviors; Harm Reduction; Toxic Effect of Tobacco and Nicotine; Carcinogenesis

Summary: this study aims to assess the feasibility, acceptability, and the potential harm reduction of switching to potentially lower risk, oral nicotine pouches in adult smokers. part one of this study aims to assess the interest of current smokers in switching to an e-cigarette device (i.e. juul) compared to alternative non-combustible tobacco products (i.e. smokeless tobacco/snus) and/or medicinal nicotine via survey. part two will consist of a pilot study of 30 non-treatment seeking adult smokers to investigate within-person changes in smoking behavior as a result of switching to different concentrations of oral nicotine pouch products (i.e. zyn, 3mg and 6mg nicotine concentration). additionally, by measuring bio-markers of tobacco exposure from baseline, this will allow the study to assess the potential for harm reduction in switching from cigarettes to oral nicotine pouches.


Eligibility criteria:
inclusion criteria: 1. 21-77 years old(in line with nih guidelines for 18+ being the age of consent in adults) (2008 phs guideline update panel) 2. english literate 3. smoke at least 1 cigarette per day 4. expired breath carbon monoxide level ≥ 6ppm at baseline 5. not currently actively pursuing smoking cessation services or planning to use evidence-based cessation tools to quit in the next month 6. not interested in the use of existing fda-approved tobacco pharmacotherapies (i.e., nrt, wellbutrin, varenicline). exclusion criteria: 1. currently using any stop smoking treatments (2008 phs guideline update panel) 2. history of serious psychiatric condition (i.e., bipolar disorder, schizophrenia) 3. current uncontrolled medical condition 4. cardiac conditions that required a hospitalization or intensive treatment on an outpatient basis in the past year including: myocardial infarction, coronary artery disease, unstable angina, congestive heart failure, or tachyarrhythmias (including rapid atrial fibrillation, ventricular tachycardia, or ventricular fibrillation) 5. female participants of child-bearing age will be excluded if they are currently pregnant or breastfeeding or report an unwillingness to use effective birth control (i.e., abstinence, iud, implant, sterilization, pill, patch, ring, or barrier method such as condoms) for the duration of the study 6. severe lung disease that requires supplemental oxygen 7. uncontrolled asthma (\<20 on the asthma control test (act) or requiring steroids more than 1x per year) 8. unstable copd: defined as gold category c or d (more than 2 exacerbations or 1 exacerbation leading to hospitalization in the past year) 9. planning to quit smoking with a set goal or time for quit attempt 10. known hypersensitivity to propylene glycol 11. patients with an fev1 \< 40%
bimatoprost as a treatment for graves' orbitopathy

Conditions: Graves Ophthalmopathy

Summary: testing whether bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with graves' disease


Eligibility criteria:
inclusion criteria: graves' ophthalmopathy with exophthalmos/proptosis - exclusion criteria: active graves disease, currently pregnant, taking steroids -
effect of different food compositions on bioavailability of biil 284 bs in healthy male volunteers

Conditions: Healthy

Summary: food effect, relative bioavailability, pharmacokinetics, safety and tolerability


Eligibility criteria:
inclusion criteria: * all participants in the study should be healthy caucasian males as determined by the results of screening, range from 21 to 50 years of age and be within +- 20% of their normal weight (broca-index) * all volunteers will have given their written informed consent in accordance with good clinical practice and local legislation prior to admission to the study exclusion criteria: * any finding of the medical examination (including blood pressure, pulse rate and ecg) deviating from normal and of clinical relevance * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * history of orthostatic hypotension, fainting spells or blackouts * chronic or relevant acute infections * history of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * intake of drugs with a long half-life (\> 24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study * use of any drugs which might influence the results of the trial (\<= one week prior to administration or during the trial) * participation in another trial with an investigational drug (\<= two months prior to administration or during the trial) * smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day) * inability to refrain from smoking on trial days * alcohol abuse (\> 60 g/day) * drug abuse * blood donation (\>= 100 ml within four weeks prior to administration or during the trial) * excessive physical activities (within the last week before the study) * any laboratory value outside the reference range of clinical relevance
effects of water-soluble olive extract supplementation

Conditions: Healthy

Summary: six weeks of supplementation of an olive extract will: * improve antioxidant status * reduce inflammation * reduce muscle damage * improve exercise performance * improve exercise recovery as compared to a placebo.


Eligibility criteria:
inclusion criteria: * recreational exerciser * bmi \<= 30 * non-smoker exclusion criteria: * blood pressure over 140/90 * type i or type ii diabetes * renal, hepatic or cardiac disease * current infectious disease

Keywords: olive antioxidant exercise inflammation recovery healthy men